The abstract is read at the publisher; the summary is JClub's.
Decision-making for systemic therapy in older adults with early-stage breast cancer must balance recurrence risk against chemotherapy harms, with evidence gaps shaping care choices.
- Why it matters: Older adults are underrepresented in therapeutic trials, leaving uncertainty about cytotoxic chemotherapy, de-escalated regimens, and targeted strategies for different tumor subtypes.
- What they did: This review synthesizes evidence for subtype-specific management, including adjuvant cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive disease and neoadjuvant pembrolizumab in triple-negative breast cancer, and presents decision-support and supportive-care tools.
- The result: It emphasizes avoiding overtreatment when less intensive approaches may suffice for lower-risk cancers or when toxicity risk is high, while warning that undertreatment in higher-risk cancers may increase breast cancer-related mortality.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.